Global Parenteral PrEP Market Growth 2026-2032

January 2026 | 78 pages | ID: PB4E1DD59AA8EN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Parenteral PrEP market size is predicted to grow from US$ 285 million in 2025 to US$ 787 million in 2032; it is expected to grow at a CAGR of 15.7% from 2026 to 2032.

Parenteral PrEP refers to HIV pre-exposure prophylaxis delivered via non-enteral routes?most commonly long-acting intramuscular injections, and in broader usage also implants or other sustained-release parenteral platforms?designed to maintain protective drug concentrations over extended intervals before potential HIV exposure occurs. In practice today, the term largely maps to long-acting injectable PrEP (e.g., long-acting cabotegravir), with the wider pipeline including implants and long-acting biologics. The central problem it addresses is not the pharmacologic efficacy of PrEP per se (daily oral PrEP is highly effective when taken as prescribed), but the implementation gap: adherence burden, missed doses, access continuity, and privacy/stigma concerns that can reduce real-world effectiveness; by shifting protection from ?remember a pill every day? to ?receive a dose every 1?2 months (or longer),? parenteral PrEP aims to deliver more consistent coverage and simplify prevention for people who struggle with, dislike, or cannot safely sustain oral regimens.In 2025, the global production capacity of parenteral PrEP reached 150,000 doses, while total sales amounted to 109,800 doses. The average selling price was USD 2,650 per dose, and the gross margin of manufacturers ranged between 60% and 70%.

The current parenteral PrEP market is in a transitional phase where clinical effectiveness is well established, but health systems and delivery models are still adapting to long-acting prevention. Acceptance among clinicians, public health authorities, and at-risk communities has grown steadily, particularly in populations where daily oral PrEP has faced adherence or continuity challenges. At the same time, the market shows a clear dual-track pattern: in higher-income settings, parenteral PrEP is typically integrated into structured medical care with an emphasis on monitoring and long-term management, while in resource-limited or high-incidence settings it is often embedded within public health programs aimed at reducing population-level transmission and stigma. As a result, uptake is shaped less by lack of interest than by variation in system readiness to support repeat dosing, follow-up, and logistics.

Looking ahead, the market is expected to evolve from reliance on a single dominant modality toward a landscape where multiple long-acting technologies coexist. Injectable approaches are likely to remain central in the near term, but innovation is increasingly focused on extending dosing intervals, offering alternative delivery formats, and pairing biomedical prevention with digital follow-up and community-based services. Parenteral PrEP is gradually being repositioned from a simple substitute for oral regimens to a flexible prevention option that can be tailored to different risk profiles, life circumstances, and care settings. Over time, competitive differentiation is likely to hinge on user experience and service integration, including convenience, discretion, and reduced long-term burden on both patients and providers.

The main drivers of this market include the persistent gap between proven efficacy and real-world adherence, growing policy emphasis on sustainable HIV prevention strategies, and ongoing advances in drug formulation and delivery science. At the same time, several constraints continue to shape adoption, such as dependence on healthcare infrastructure, the need for trained personnel and regular follow-up, social stigma and uneven awareness, and concerns around long-term safety or reversibility among certain users. The interaction of these forces suggests that growth in parenteral PrEP will be evolutionary rather than abrupt, unfolding alongside broader changes in health policy, service delivery, and social acceptance rather than through rapid, uniform expansion.

LP Information, Inc. (LPI) ' newest research report, the ?Parenteral PrEP Industry Forecast? looks at past sales and reviews total world Parenteral PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Parenteral PrEP sales for 2026 through 2032. With Parenteral PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parenteral PrEP industry.

This Insight Report provides a comprehensive analysis of the global Parenteral PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Parenteral PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Parenteral PrEP market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parenteral PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parenteral PrEP.

This report presents a comprehensive overview, market shares, and growth opportunities of Parenteral PrEP market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
  • Cabotegravir
  • Lenacapavir
  • Other
Segmentation by Dosing Interval:
  • Short-interval Injections
  • Monthly Injections
  • Quarterly Injections
Segmentation by Drug Properties:
  • Original Drug
  • Generic Drug
Segmentation by Application:
  • Subcutaneous Use
  • Intramuscular Use
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
  • Gilead Sciences
  • ViiV Healthcare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Parenteral PrEP market?
What factors are driving Parenteral PrEP market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Parenteral PrEP market opportunities vary by end market size?
How does Parenteral PrEP break out by Type, by Application?
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Parenteral PrEP Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Parenteral PrEP by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Parenteral PrEP by Country/Region, 2021, 2025 & 2032
2.2 Parenteral PrEP Segment by Type
  2.2.1 Cabotegravir
  2.2.2 Lenacapavir
  2.2.3 Other
  2.2.4 Parenteral PrEP Sales by Type
    2.2.4.1 Global Parenteral PrEP Sales Market Share by Type (2021-2026)
    2.2.4.2 Global Parenteral PrEP Revenue and Market Share by Type (2021-2026)
    2.2.4.3 Global Parenteral PrEP Sale Price by Type (2021-2026)
2.3 Parenteral PrEP Segment by Dosing Interval
  2.3.1 Short-interval Injections
  2.3.2 Monthly Injections
  2.3.3 Quarterly Injections
  2.3.4 Parenteral PrEP Sales by Dosing Interval
    2.3.4.1 Global Parenteral PrEP Sales Market Share by Dosing Interval (2021-2026)
    2.3.4.2 Global Parenteral PrEP Revenue and Market Share by Dosing Interval (2021-2026)
    2.3.4.3 Global Parenteral PrEP Sale Price by Dosing Interval (2021-2026)
2.4 Parenteral PrEP Segment by Drug Properties
  2.4.1 Original Drug
  2.4.2 Generic Drug
  2.4.3 Parenteral PrEP Sales by Drug Properties
    2.4.3.1 Global Parenteral PrEP Sales Market Share by Drug Properties (2021-2026)
    2.4.3.2 Global Parenteral PrEP Revenue and Market Share by Drug Properties (2021-2026)
    2.4.3.3 Global Parenteral PrEP Sale Price by Drug Properties (2021-2026)
2.5 Parenteral PrEP Segment by Application
  2.5.1 Subcutaneous Use
  2.5.2 Intramuscular Use
  2.5.3 Parenteral PrEP Sales by Application
    2.5.3.1 Global Parenteral PrEP Sale Market Share by Application (2021-2026)
    2.5.3.2 Global Parenteral PrEP Revenue and Market Share by Application (2021-2026)
    2.5.3.3 Global Parenteral PrEP Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Parenteral PrEP Breakdown Data by Company
  3.1.1 Global Parenteral PrEP Annual Sales by Company (2021-2026)
  3.1.2 Global Parenteral PrEP Sales Market Share by Company (2021-2026)
3.2 Global Parenteral PrEP Annual Revenue by Company (2021-2026)
  3.2.1 Global Parenteral PrEP Revenue by Company (2021-2026)
  3.2.2 Global Parenteral PrEP Revenue Market Share by Company (2021-2026)
3.3 Global Parenteral PrEP Sale Price by Company
3.4 Key Manufacturers Parenteral PrEP Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Parenteral PrEP Product Location Distribution
  3.4.2 Players Parenteral PrEP Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PARENTERAL PREP BY GEOGRAPHIC REGION

4.1 World Historic Parenteral PrEP Market Size by Geographic Region (2021-2026)
  4.1.1 Global Parenteral PrEP Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Parenteral PrEP Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Parenteral PrEP Market Size by Country/Region (2021-2026)
  4.2.1 Global Parenteral PrEP Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Parenteral PrEP Annual Revenue by Country/Region (2021-2026)
4.3 Americas Parenteral PrEP Sales Growth
4.4 APAC Parenteral PrEP Sales Growth
4.5 Europe Parenteral PrEP Sales Growth
4.6 Middle East & Africa Parenteral PrEP Sales Growth

5 AMERICAS

5.1 Americas Parenteral PrEP Sales by Country
  5.1.1 Americas Parenteral PrEP Sales by Country (2021-2026)
  5.1.2 Americas Parenteral PrEP Revenue by Country (2021-2026)
5.2 Americas Parenteral PrEP Sales by Type (2021-2026)
5.3 Americas Parenteral PrEP Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Parenteral PrEP Sales by Region
  6.1.1 APAC Parenteral PrEP Sales by Region (2021-2026)
  6.1.2 APAC Parenteral PrEP Revenue by Region (2021-2026)
6.2 APAC Parenteral PrEP Sales by Type (2021-2026)
6.3 APAC Parenteral PrEP Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Parenteral PrEP by Country
  7.1.1 Europe Parenteral PrEP Sales by Country (2021-2026)
  7.1.2 Europe Parenteral PrEP Revenue by Country (2021-2026)
7.2 Europe Parenteral PrEP Sales by Type (2021-2026)
7.3 Europe Parenteral PrEP Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Parenteral PrEP by Country
  8.1.1 Middle East & Africa Parenteral PrEP Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Parenteral PrEP Revenue by Country (2021-2026)
8.2 Middle East & Africa Parenteral PrEP Sales by Type (2021-2026)
8.3 Middle East & Africa Parenteral PrEP Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Parenteral PrEP
10.3 Manufacturing Process Analysis of Parenteral PrEP
10.4 Industry Chain Structure of Parenteral PrEP

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Parenteral PrEP Distributors
11.3 Parenteral PrEP Customer

12 WORLD FORECAST REVIEW FOR PARENTERAL PREP BY GEOGRAPHIC REGION

12.1 Global Parenteral PrEP Market Size Forecast by Region
  12.1.1 Global Parenteral PrEP Forecast by Region (2027-2032)
  12.1.2 Global Parenteral PrEP Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Parenteral PrEP Forecast by Type (2027-2032)
12.7 Global Parenteral PrEP Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Gilead Sciences
  13.1.1 Gilead Sciences Company Information
  13.1.2 Gilead Sciences Parenteral PrEP Product Portfolios and Specifications
  13.1.3 Gilead Sciences Parenteral PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 Gilead Sciences Main Business Overview
  13.1.5 Gilead Sciences Latest Developments
13.2 ViiV Healthcare
  13.2.1 ViiV Healthcare Company Information
  13.2.2 ViiV Healthcare Parenteral PrEP Product Portfolios and Specifications
  13.2.3 ViiV Healthcare Parenteral PrEP Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 ViiV Healthcare Main Business Overview
  13.2.5 ViiV Healthcare Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Parenteral PrEP Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Parenteral PrEP Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cabotegravir
Table 4. Major Players of Lenacapavir
Table 5. Major Players of Other
Table 6. Global Parenteral PrEP Sales by Type (2021-2026) & (K Dose)
Table 7. Global Parenteral PrEP Sales Market Share by Type (2021-2026)
Table 8. Global Parenteral PrEP Revenue by Type (2021-2026) & ($ million)
Table 9. Global Parenteral PrEP Revenue Market Share by Type (2021-2026)
Table 10. Global Parenteral PrEP Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Short-interval Injections
Table 12. Major Players of Monthly Injections
Table 13. Major Players of Quarterly Injections
Table 14. Global Parenteral PrEP Sales by Dosing Interval (2021-2026) & (K Dose)
Table 15. Global Parenteral PrEP Sales Market Share by Dosing Interval (2021-2026)
Table 16. Global Parenteral PrEP Revenue by Dosing Interval (2021-2026) & ($ million)
Table 17. Global Parenteral PrEP Revenue Market Share by Dosing Interval (2021-2026)
Table 18. Global Parenteral PrEP Sale Price by Dosing Interval (2021-2026) & (US$/Dose)
Table 19. Major Players of Original Drug
Table 20. Major Players of Generic Drug
Table 21. Global Parenteral PrEP Sales by Drug Properties (2021-2026) & (K Dose)
Table 22. Global Parenteral PrEP Sales Market Share by Drug Properties (2021-2026)
Table 23. Global Parenteral PrEP Revenue by Drug Properties (2021-2026) & ($ million)
Table 24. Global Parenteral PrEP Revenue Market Share by Drug Properties (2021-2026)
Table 25. Global Parenteral PrEP Sale Price by Drug Properties (2021-2026) & (US$/Dose)
Table 26. Global Parenteral PrEP Sale by Application (2021-2026) & (K Dose)
Table 27. Global Parenteral PrEP Sale Market Share by Application (2021-2026)
Table 28. Global Parenteral PrEP Revenue by Application (2021-2026) & ($ million)
Table 29. Global Parenteral PrEP Revenue Market Share by Application (2021-2026)
Table 30. Global Parenteral PrEP Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Parenteral PrEP Sales by Company (2021-2026) & (K Dose)
Table 32. Global Parenteral PrEP Sales Market Share by Company (2021-2026)
Table 33. Global Parenteral PrEP Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Parenteral PrEP Revenue Market Share by Company (2021-2026)
Table 35. Global Parenteral PrEP Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Parenteral PrEP Producing Area Distribution and Sales Area
Table 37. Players Parenteral PrEP Products Offered
Table 38. Parenteral PrEP Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Parenteral PrEP Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global Parenteral PrEP Sales Market Share Geographic Region (2021-2026)
Table 43. Global Parenteral PrEP Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Parenteral PrEP Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Parenteral PrEP Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global Parenteral PrEP Sales Market Share by Country/Region (2021-2026)
Table 47. Global Parenteral PrEP Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Parenteral PrEP Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Parenteral PrEP Sales by Country (2021-2026) & (K Dose)
Table 50. Americas Parenteral PrEP Sales Market Share by Country (2021-2026)
Table 51. Americas Parenteral PrEP Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Parenteral PrEP Sales by Type (2021-2026) & (K Dose)
Table 53. Americas Parenteral PrEP Sales by Application (2021-2026) & (K Dose)
Table 54. APAC Parenteral PrEP Sales by Region (2021-2026) & (K Dose)
Table 55. APAC Parenteral PrEP Sales Market Share by Region (2021-2026)
Table 56. APAC Parenteral PrEP Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Parenteral PrEP Sales by Type (2021-2026) & (K Dose)
Table 58. APAC Parenteral PrEP Sales by Application (2021-2026) & (K Dose)
Table 59. Europe Parenteral PrEP Sales by Country (2021-2026) & (K Dose)
Table 60. Europe Parenteral PrEP Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Parenteral PrEP Sales by Type (2021-2026) & (K Dose)
Table 62. Europe Parenteral PrEP Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa Parenteral PrEP Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa Parenteral PrEP Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Parenteral PrEP Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa Parenteral PrEP Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of Parenteral PrEP
Table 68. Key Market Challenges & Risks of Parenteral PrEP
Table 69. Key Industry Trends of Parenteral PrEP
Table 70. Parenteral PrEP Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Parenteral PrEP Distributors List
Table 73. Parenteral PrEP Customer List
Table 74. Global Parenteral PrEP Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global Parenteral PrEP Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Parenteral PrEP Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas Parenteral PrEP Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Parenteral PrEP Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC Parenteral PrEP Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Parenteral PrEP Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe Parenteral PrEP Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Parenteral PrEP Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa Parenteral PrEP Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Parenteral PrEP Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global Parenteral PrEP Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Parenteral PrEP Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global Parenteral PrEP Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Gilead Sciences Basic Information, Parenteral PrEP Manufacturing Base, Sales Area and Its Competitors
Table 89. Gilead Sciences Parenteral PrEP Product Portfolios and Specifications
Table 90. Gilead Sciences Parenteral PrEP Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Gilead Sciences Main Business
Table 92. Gilead Sciences Latest Developments
Table 93. ViiV Healthcare Basic Information, Parenteral PrEP Manufacturing Base, Sales Area and Its Competitors
Table 94. ViiV Healthcare Parenteral PrEP Product Portfolios and Specifications
Table 95. ViiV Healthcare Parenteral PrEP Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. ViiV Healthcare Main Business
Table 97. ViiV Healthcare Latest Developments

LIST OF FIGURES

Figure 1. Picture of Parenteral PrEP
Figure 2. Parenteral PrEP Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Parenteral PrEP Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Parenteral PrEP Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Parenteral PrEP Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Parenteral PrEP Sales Market Share by Country/Region (2025)
Figure 10. Parenteral PrEP Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cabotegravir
Figure 12. Product Picture of Lenacapavir
Figure 13. Product Picture of Other
Figure 14. Global Parenteral PrEP Sales Market Share by Type in 2026
Figure 15. Global Parenteral PrEP Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Short-interval Injections
Figure 17. Product Picture of Monthly Injections
Figure 18. Product Picture of Quarterly Injections
Figure 19. Global Parenteral PrEP Sales Market Share by Dosing Interval in 2026
Figure 20. Global Parenteral PrEP Revenue Market Share by Dosing Interval (2021-2026)
Figure 21. Product Picture of Original Drug
Figure 22. Product Picture of Generic Drug
Figure 23. Global Parenteral PrEP Sales Market Share by Drug Properties in 2026
Figure 24. Global Parenteral PrEP Revenue Market Share by Drug Properties (2021-2026)
Figure 25. Parenteral PrEP Consumed in Subcutaneous Use
Figure 26. Global Parenteral PrEP Market: Subcutaneous Use (2021-2026) & (K Dose)
Figure 27. Parenteral PrEP Consumed in Intramuscular Use
Figure 28. Global Parenteral PrEP Market: Intramuscular Use (2021-2026) & (K Dose)
Figure 29. Global Parenteral PrEP Sale Market Share by Application (2025)
Figure 30. Global Parenteral PrEP Revenue Market Share by Application in 2026
Figure 31. Parenteral PrEP Sales by Company in 2026 (K Dose)
Figure 32. Global Parenteral PrEP Sales Market Share by Company in 2026
Figure 33. Parenteral PrEP Revenue by Company in 2026 ($ millions)
Figure 34. Global Parenteral PrEP Revenue Market Share by Company in 2026
Figure 35. Global Parenteral PrEP Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Parenteral PrEP Revenue Market Share by Geographic Region in 2026
Figure 37. Americas Parenteral PrEP Sales 2021-2026 (K Dose)
Figure 38. Americas Parenteral PrEP Revenue 2021-2026 ($ millions)
Figure 39. APAC Parenteral PrEP Sales 2021-2026 (K Dose)
Figure 40. APAC Parenteral PrEP Revenue 2021-2026 ($ millions)
Figure 41. Europe Parenteral PrEP Sales 2021-2026 (K Dose)
Figure 42. Europe Parenteral PrEP Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Parenteral PrEP Sales 2021-2026 (K Dose)
Figure 44. Middle East & Africa Parenteral PrEP Revenue 2021-2026 ($ millions)
Figure 45. Americas Parenteral PrEP Sales Market Share by Country in 2026
Figure 46. Americas Parenteral PrEP Revenue Market Share by Country (2021-2026)
Figure 47. Americas Parenteral PrEP Sales Market Share by Type (2021-2026)
Figure 48. Americas Parenteral PrEP Sales Market Share by Application (2021-2026)
Figure 49. United States Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Parenteral PrEP Sales Market Share by Region in 2026
Figure 54. APAC Parenteral PrEP Revenue Market Share by Region (2021-2026)
Figure 55. APAC Parenteral PrEP Sales Market Share by Type (2021-2026)
Figure 56. APAC Parenteral PrEP Sales Market Share by Application (2021-2026)
Figure 57. China Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 61. India Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Parenteral PrEP Sales Market Share by Country in 2026
Figure 65. Europe Parenteral PrEP Revenue Market Share by Country (2021-2026)
Figure 66. Europe Parenteral PrEP Sales Market Share by Type (2021-2026)
Figure 67. Europe Parenteral PrEP Sales Market Share by Application (2021-2026)
Figure 68. Germany Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 69. France Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Parenteral PrEP Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Parenteral PrEP Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Parenteral PrEP Sales Market Share by Application (2021-2026)
Figure 76. Egypt Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Parenteral PrEP Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Parenteral PrEP in 2026
Figure 82. Manufacturing Process Analysis of Parenteral PrEP
Figure 83. Industry Chain Structure of Parenteral PrEP
Figure 84. Channels of Distribution
Figure 85. Global Parenteral PrEP Sales Market Forecast by Region (2027-2032)
Figure 86. Global Parenteral PrEP Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Parenteral PrEP Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Parenteral PrEP Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Parenteral PrEP Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Parenteral PrEP Revenue Market Share Forecast by Application (2027-2032)